Peer-influenced content. Sources you trust. No registration required. This is HCN.
Cleveland Clinic Journal of Medicine
Current research underscores the importance of individualized patient care and shared decision-making in managing hypertension, with no conclusive evidence favoring either morning or evening dosing of antihypertensive medications.
Cardiology January 4th 2024
The Epoch Times
Stay informed about recent recalls to ensure patient safety. Learn more about the recall of a blood pressure medication contaminated with oxycodone.
Cardiology October 11th 2023
Annals of Internal Medicine
A recent Swedish study reveals a significant, graded association between elevated blood pressure in late adolescence and future cardiovascular risks. Early intervention may be key to mitigating long-term health outcomes.
Cardiology October 4th 2023
This pooled analysis provides robust evidence that low-dose glucocorticoids in RA treatment result in modest weight gain but do not elevate blood pressure. Consider these findings in your risk-benefit discussions with patients.
Clinical Pharmacology August 31st 2023
JAMA Network
Diving into intensive systolic BP treatment unveils intriguing cognitive benefits according to a secondary analysis of the SPRINT trial. The SPRINT trial has shed fresh light on the impact of intensive systolic blood pressure (SBP) treatment on cognitive health. Out of 7,918 participants, a significant majority with higher baseline risk of dementia or mild cognitive impairment (MCI) revealed marked cognitive improvements with intensive SBP treatment. This marks a leap forward in understanding SBP treatment’s role in cognitive function preservation. In the comprehensive secondary analysis, patients were meticulously followed up over a median of four years. To streamline the study, two SBP treatment targets were identified: intensive, set at less than 120 mm Hg, and standard, at less than 140 mm Hg. The data collected showcased 765 and 828 primary outcome events in intensive and standard treatment groups, respectively. Consequently, it confirmed intensive SBP treatment’s potential in reducing the risk of MCI or dementia. Digging deeper into the data, certain trends emerged. Older age, Medicare enrollment, and higher baseline serum creatinine levels correlated with a higher risk of the primary outcome. Conversely, enhanced baseline cognitive functioning and active employment status signified lower risk. Interestingly, higher baseline risk connected directly with greater […]
Cardiology May 23rd 2023
There haven’t been any national guidelines developed for managing patients with stage 1 hypertension who don’t respond to lifestyle modification. This population represents an important guideline gap: most patients with stage 1 hypertension progress to stage 2 hypertension, which increases the risk for cardiovascular events. The AHA has published a scientific statement to fill the gap – if lifestyle modification fails to reduce blood pressure, consider pharmacotherapy.
Cardiology May 17th 2022